Signup to receive the UMDF newsletter in your email monthly at umdf.org/newsletter-signup. Meet Us At MitoMed 2026 in Orlando, FL Registration...
Read: March 2026 Newsletter: Mito Med Conference, Volunteer Awards, AdvocacyUMDF is disappointed by the U.S. Food and Drug Administration’s (FDA) decision not to approve idebenone for Leber Hereditary Optic Neuropathy...
Read: UMDF, LHON Collective Issue Statement on the FDA’s Decision Not to Approve IdebenoneSignup to receive the UMDF newsletter in your email monthly at umdf.org/newsletter-signup. February is National Heart Month and Rare Disease...
Read: February 2026 Newsletter: Rare Disease Awareness, Advocacy Updates, and MoreSignup to receive the UMDF newsletter in your email monthly at umdf.org/newsletter-signup. UMDF Marks 30 Years of Serving the Mitochondrial...
Read: January 2026 Newsletter: UMDF Turns 30, Legislation We’re Watching in 2026, Nutrition Survey, and MoreSignup to receive the UMDF newsletter in your email monthly at umdf.org/newsletter-signup. NY Jets Player and Coach Team Up to Support Mito...
Read: December 2025 Newsletter: NY Jets Bring Mito Awareness, New Research Grants, Clinical Trials Updates, and moreUMDF has teamed up with the Muscular Dystrophy Association (MDA) to co-fund two new research projects to accelerate the development of...
Read: UMDF Partners with MDA to Co-Fund Two New Mito Research GrantsSignup to receive the UMDF newsletter in your email monthly at umdf.org/newsletter-signup. FDA Approves First-Ever TK2d Therapy Earlier this...
Read: Your November UMDF Newsletter: Celebrating a TK2d Therapy Approval, MELAS Survey, Mito Books, and More11/3/25, 5pm EST — Earlier today, the U.S. Food and Drug Administration (FDA) approved UCB’s Kygevvi (doxecitine and doxribtimine) to...
Read: FDA Approves First-Ever TK2d Therapy